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The pernicious effects of lead on the health of
children are well-documented. The severity of many
of these effects directly correlates with increasing
blood lead levels (BLLs). The current
recommendation from the Centers for Disease
Control and Prevention (CDC) and the American
Academy of Pediatrics (AAP) is that BLLs 10 g/dL
are dangerous.1 However, new evidence
demonstrates that there is no safe BLL and that
children with BLLs <10 g/dL exhibit neurological
and social deficits.2 The Vermont Department of
Health (VDH) currently recommends universal blood
lead screening for 12 and 24 month-old children.3  In
2006, 79% of 12 month-old children and 41% of 24
month-old children were screened in Vermont.
To identify barriers preventing Vermont
pediatricians from performing blood lead
screening on 24 month-old children.
To identify specific predictors associated with
lower rates of screening using data from a
descriptive population study.
While data collection often presents many
challenges, the use of a web-based survey was an
effective and timely method for gathering
information regarding physician opinion. Data
analysis and subsequent interpretation in light of
public policy proved more difficult than anticipated.
A web-based survey was distributed to all
currently licensed Vermont primary care
pediatricians to obtain descriptive information
regarding current lead screening practices.
Pediatricians were assigned to a higher, lower or
unknown screening group based on blood lead
screening rates from the Vermont Immunization
Registry and the Childhood Lead Poisoning
Prevention Program Registry.
Univariate and multivariate analyses were used to
assess factors associated with higher versus
lower blood lead screening rates.
1 CDC. Preventing Lead Poisoning in Young Children: A Statement by the Centers for Disease Control.
Atlanta, GA:Centers for Disease Control and Prevention. 1991.
2 Chiodo LM, Covington C, Sokol RJ, Hannigan JH, Jannise J, Ager J, et al. Blood lead levels and
specific attention effects in young children. Neurotoxicol Teratol 2007;29(5):538-46.
3 Campbell JR, Schaffer SJ, Szilagyi PG, O’Conner, KG, Briss P, Weitzman, M. Blood lead screening
practices among US pediatricians. Pediatrics 1996;98:372-377.
4 Office of Vermont Health Access.
72 out of 98 pediatricians responded (~74%).
Factors associated with lower lead screening rates
included practicing in Chittenden County, belonging to a
non-academic group practice and having a low self-
reported Medicaid population (Table 1).
52.8% of pediatricians believed that they are not
adequately reimbursed for blood lead screening. The
reported mean cost of screening per patient was $22.30,
while the desired reimbursement amount was $27.30 (the
current Medicaid reimbursement rate is $4.00).4
Pediatricians were more likely to be in the higher
screening group if they reported that a BLL 10g/dL is
associated with negative health outcomes, reported
agreeing with the VDH lead screening
While survey data demonstrate that 50% of
Vermont pediatricians disagreed with the VDH
blood lead screening recommendations, the
majority of respondents (88%) reported using the
VDH as a primary source of information and
guidance when establishing office policy.
Therefore, the VDH has an opportunity to redesign
its physician education to convey the importance of
universal lead screening at 24 months through
emphasis on the significant health risks associated
with BLLs 10g/dL. Multivariate analysis also
indicates that physicians with larger Medicaid
populations have significantly higher screening
rates. We recommend that the VDH further
investigate this association to determine strategies










Respondents were assigned to screening groups
based on practice screening rates. Thus, while
pediatricians practicing independently are
accurately represented by these figures, those in
group practice may have been assigned rates that
are not representative of their individual
screening.
“Higher” screening was defined as a rate above
the median (37.5%), thus many individuals in this
group may still be far from achieving ideal
screening practices.
recommendations, or reported routinely screening all 24
month-old children for blood lead (Table 2).
The three most-reported barriers to lead screening were
parental opposition, difficulty obtaining samples and no
risk on assessment (Table 3).
Multivariate analysis indicated that the most significant
determinants of lower versus higher screening rates are
gender of the pediatrician (contributes 9%), perceived
dangerous BLL (contributes 28%) and self-reported
Medicaid population (contributes 63%) (Table 4).
The top two sources of lead screening information
utilized by pediatricians in this study were the VDH (88%)
and the AAP (69%).
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95% CI Adjusted POR Adj. 95% CI Coefficient¥ Std. Err. p-value
0.39 to 3.07 8.39 1.11 to 62.92 2.13 1.03 0.039
1.26 to 10.47 43.06 4.03 to 460.09 3.76 1.21 0.002
0.004 to 0.34 0.007 0.000 to 0.131 -4.96 1.49 0.001
0.001 to 0.14 0.001 0.000 to <0.0001 -7.07 1.85 <0.001
3.64
¥
 Coefficients are used to predict Lower vs. Higher individual pediatrician’s practice screening rate. Sex (1 if male); Lead level (1 if >10 g/dL); 2nd Medicaid tercile 
(1 if Yes); 3
rd
 Medicaid tercile (1 if Yes). P>0.5 suggests a 24 month year old screening rate <37.5% [Sensitivity=0.90, Specificity=0.83, Positive Predictive Value 
(PPV)=0.85, Negative Predictive Value (NPV)=0.89]
Perceived lead level at which 















Proportion of patient population 
on Medicaid
1.09
TABLE 4: Logistic regression analysis of determinants associated with lower lead screening
in 61 Vermont primary-care pediatricians
Description of Pediatric Practices N % N % N % Prevalence Odds Ratio 95% CI†
Reported blood lead level at which risk for negative health 
outcomes begins (>10 μg/dL) 36 50 10 33.3 20 64.5 3.64 1.12-11.99
Reported routinely screen 12 month olds 61 84.7 28 93.3 24 77.4 0.24 0.05-1.29
Reported routinely screen 24 month olds 37 51.4 20 66.7 12 38.7 0.32 0.11-0.90
Collected blood samples in Office 60 83.3 25 83.3 26 83.9 1.04 0.27-4.03
Collected blood samples at hospital 43 59.7 20 66.7 16 51.6 0.53 0.19-1.50
Collected blood samples at public health/WIC clinic 61 84.7 26 86.7 26 83.9 0.8 0.19-3.32
Reported adequate reimbursement for lead screening 38 52.9 14 46.7 18 58.1 1.58 0.58-4.35
Report that there is sufficient evidence to warrant universal 
blood lead screening in VT children 61 84.7 25 83.3 27 87.1 1.35 0.33-5.60
Reported awareness of the VDH's current lead screening 
recommendation 64 88.9 30 100 25 80.7 § §
Reported agreement with the current VDH 
recommendation 36 50 21 70 10 32.3 0.2 0.07-0.60
†PRs calculated to compare participants who had higher and lower screening rates.  Bold type indicates statistical significance (CI excludes the null).  
§Variable predicts outcome perfectly.
All (n=72) Higher screening (n=30*) Lower screening (n=31*)
*Information on screening rate is unknown for 11 respondents.
TABLE 2: Prevalence Odds Ratios (POR) for Vermont pediatricians as indicators of lower blood screening
Higher screening Lower screening 
(n=30*) (n=31*)
40.3 36.7 38.71 ns (0.87)
52.8 60 48.39 ns (0.36)
44.4 46.7 41.94 ns (0.71)
37.5 26.7 54.84 0.025
15.3 26.7 9.68 ns (0.08)
73.6 60 83.87 0.04












Years in practice (%   15)
Age (%  50 years)
Residency training city size
(%   500,000 people)
Academic practice (%)
Group practice (non-academic) (%)
Proportion of patient
†p-values calculated to compare participants who had higher and lower screening rates.  Bold type   





*Information on screening rate is unknown for 11 respondents.
<0.001
3rd tercile (54-100%)
TABLE 1: Demographic characteristics of survey respondents
Self-reported barriers to lead screening
(% Reporting)
Parental opposition 79.2 90 71 ns (0.06)
No exposure/risk on assessment 58.3 66.7 51.6 ns (0.23)
Difficulty obtaining sample 55.6 66.7 41.9 0.05
Patient compliance 49.7 70 51.6 ns (0.14)
Staffing 48.6 63.3 38.7 0.05
Time 47.2 56.7 41.9 ns (0.25)
Cost to physician 41.7 53.3 35.5 ns (0.16)
Cost to patient 37.5 46.7 32.3 ns (0.25)
*Information on screening rate is unknown for 11 respondents.
†p-values calculated to compare participants who had higher and lower screening rates.  Bold type indicates   







TABLE 3: Percent of respondents reporting any influence of eight common
barriers on his/her blood lead screening practices
